Cybin (HELP) Net Equity Issued and Repurchased (2020 - 2025)
Cybin's (HELP) quarterly Net Equity Issued and Repurchased came in at $135.9 million in Q4 2025, up 1241.35% on a QoQ basis from $10.1 million in Q2 2025.
Cybin (HELP) Net Equity Issued and Repurchased (2020 - 2025) Analysis & Trends
Cybin (HELP) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $135.9 million in Q4 2025.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $135.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $175.2 million (changed N/A YoY) and the FY2022 annual result came in at $42.9 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased improved to $135.9 million in Q4 2025, from $10.1 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $135.9 million in Q4 2025 to a low of $2.5 million in Q4 2022.
- A 4-year average of $27.9 million and a median of $12.7 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased jumped 4285.05% — and 2023, when it soared 1045.56%.
- Tracing HELP's Net Equity Issued and Repurchased over 4 years: stood at $25.0 million in 2021, then plunged by 89.82% to $2.5 million in 2022, then soared by 1045.56% to $29.2 million in 2023, then soared by 365.61% to $135.9 million in 2025.
- The last three Net Equity Issued and Repurchased figures came in at $135.9 million (Q4 2025), $10.1 million (Q2 2025), and $29.2 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 135.92 Mn |
| Dec 31, 2025 | 135.92 Mn |
| Jun 30, 2025 | 10.13 Mn |
| Jun 30, 2025 | 10.13 Mn |
| Dec 31, 2023 | 29.19 Mn |
| Dec 31, 2023 | 29.19 Mn |
| Sep 30, 2023 | 15.21 Mn |
| Sep 30, 2023 | 15.21 Mn |
| Jun 30, 2023 | 2.62 Mn |
| Jun 30, 2023 | 2.62 Mn |
| Dec 31, 2022 | 2.55 Mn |
| Dec 31, 2022 | 2.55 Mn |
| Feb 28, 2022 | 2.67 Mn |
| Feb 28, 2022 | 2.67 Mn |
| Sep 30, 2021 | 25.03 Mn |
| Sep 30, 2021 | 25.03 Mn |
| Dec 31, 2020 | 33.96 Mn |
| Dec 31, 2020 | 33.96 Mn |
| Sep 30, 2020 | -598,087.67 |
| Sep 30, 2020 | -598,087.67 |